Phase 2 Randomized Double-Blind Comparison of Sirolimus-Eluting Stent Versus Bare-Metal Stent Implantation in Degenerated Saphenous Vein Grafts
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 75
- 试验地点
- 1
- 主要终点
- In-stent late loss
研究概览
简要总结
Context: Sirolimus-eluting-stents have improved the benefits of percutaneous interventions in native coronary arteries reducing the occurrence of restenosis and repeated revascularization, however saphenous vein grafts have been always excluded form randomized trials.
Objective: To evaluate the angiographic and clinical impact of sirolimus-eluting-stents with respect to bare-metal-stents in degenerated vein grafts.
Design: Double-blind randomized controlled non-industry-sponsored trial.
Setting: A single-center tertiary-care referral hospital.
Patients: All patients are randomly allocated to sirolimus-eluting-stent implantation or the corresponding bare-metal-stent. All patients are followed clinically and repeated angiographic follow-up is performed in all at 6-months.
Main outcome measure: Primary end-point is 6-months angiographic in-stent late loss. Secondary end-points include: binary angiographic in-stent and in-segment restenosis, intravascular-ultrasound-measured neo-intimal hyperplasia volume and all the clinical events (death, myocardial infarction, target-lesion and target-vessel revascularization).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 to 85 years-old
- •clear signs and/or symptoms of stable or unstable angina or documented silent ischemia
- •one or more de-novo target lesions (>50% diameter stenosis by visual estimate) localized in one or more diseased SVG with a reference vessel diameter (RVD) included between 2.5 and 4.0 mm (by visual estimate)
- •signed informed consent.
排除标准
- •Myocardial Infarction within the previous 7 days
- •documented left ventricular ejection fraction <25%
- •impaired renal function (creatinine >3.0 mg/dl) at the time of treatment
- •outflow obstruction of the graft due to distal anastomotic stenosis
- •totally occluded Saphenous Vein Graft
- •brachytherapy treatment in the index vessel before enrollment
- •life expectancy less than 12 months
- •known allergy to aspirin, clopidogrel bisulfate, heparin, stainless steel, contrast agent or sirolimus
- •hemorrhagic diatheses
- •a recent positive pregnancy test, breast-feeding, or the possibility of a future pregnancy.
结局指标
主要结局
In-stent late loss
次要结局
- in-segment late loss
- binary angiographic in-stent restenosis
- binary angiographic in-segment restenosis
- intravascular-ultrasound-measured neo-intimal hyperplasia volume
- death
- myocardial infarction
- target-lesion revascularization
- target-vessel revascularization
- stent thrombosis